Jean-Philippe Meyer

Title: Innovations of Jean-Philippe Meyer

Introduction

Jean-Philippe Meyer is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate PPAR (Peroxisome Proliferator-Activated Receptor) activity. With a total of 3 patents to his name, his work has implications for treating various diseases, including diabetes and cancer.

Latest Patents

Meyer’s latest patents include "Substituted 1,3-dioxanes useful as PPAR modulators." This invention describes specific stereoisomers of 1,3-dioxane derivatives that are beneficial in treating diseases dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders, and infections. Another significant patent is "Hepodxilin analog enantiomers," which relates to enantiomeric forms of hepoxilin analogs. This invention includes pharmaceutical compositions and methods for separating these enantiomeric forms using chiral phase HPLC columns. These hepoxilin analogs have been found useful in controlling biological effects related to PPAR-mediated transcriptional control for treating diseases like cancer and thromboxane-mediated conditions.

Career Highlights

Throughout his career, Jean-Philippe Meyer has worked with various companies, including Evolva SA. His innovative work has positioned him as a key figure in pharmaceutical research and development.

Collaborations

Meyer has collaborated with notable professionals in his field, including Peteris Alberts and Alexandra Santana Sorensen. These collaborations have likely contributed to the advancement of his research and inventions.

Conclusion

Jean-Philippe Meyer is a distinguished inventor whose work in pharmaceutical innovations has the potential to impact the treatment of several critical health conditions. His contributions to the field are noteworthy and continue to inspire further research and development.